BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
5 Pizza Fixings That Characterize Your Character - 2France bans Muslim gathering citing risk to participants
- 3Iran fires one of largest barrages in weeks ahead of Passover
- 4Kissing is an ‘evolutionary conundrum.’ Scientists just mapped its unexpected origins
- 5Artemis II astronauts arrive in Florida to prepare for launch to the moon
- Vote In favor of Your Favored Kind Of Vegetable
- Home Security Frameworks with Shrewd Elements
- Step by step instructions to Streamline Your Dozing Involvement in a Savvy Bed
- Presenting Nintendo's New Pastel Satisfaction Con Tones for Switch Gamers: 3 Upscale Choices
- Astronauts on the ISS watched NASA's historic Artemis 2 launch from space
- Canada's Friendly Sunshine Coast City Is An Outdoor Playground Perfect For Hiking And Paddling
- Vote in favor of Your Number one kind of pie
- Evaluated Smartwatches for Wellness Devotees
- 6 Exercises to Anticipate in 2024
